02487 CUTIA-B
- 7.790
- +0.030+0.39%
CUTIA-B News
Cutia Therapeutics Obesity Drug Reaches Meaningful End to Clinical Trial
Koddi-B (02487.HK): Consumer & R&D dual-drive, the strength of the pan-skin platform newcomer is promising.
Kedi Group is a rising star enterprise in the domestic pan-skin field. The company's core pipeline covers four major areas: hair, skin, fat reduction, and superficial nerve, creating an integrated dermatology platform in a vast market. The company was established in 2019 and went public on the Hong Kong Stock Exchange in June 2023.
Ketide (02487.HK) new drug CU-20401 shows significant and robust therapeutic advantages in clinical trials.
Codicil (02487.HK) announced that its potential new drug CU-20401 (recombinant mutant collagenase) undergoing Phase II clinical trial in China for treating submental fat accumulation has obtained top-line data. The data indicates that the clinical trial has achieved the primary endpoint, with results showing statistical significance and clinical relevance. Analysis results demonstrate that in terms of efficacy, the primary efficacy endpoint data show that both the low-dose CU-20401 group and the high-dose CU-20401 group have higher treatment effectiveness rates than the placebo control group, with the difference in efficacy rates being statistically significant. Secondary efficacy endpoint data also demonstrate similarities.
Kodai-B (02487.HK): The CU-20401 (recombinant mutant collagenase) treatment for submental fat accumulation reached the primary endpoint in Phase II clinical trials.
Grain 29th of November, Ke Di-B (02487.HK) announced that the group's potential class 1 new drug CU-20401 (recombinant mutant collagenase) has obtained top-line data from the phase II clinical trial for the treatment of submental fat accumulation in China. The data showed that the clinical trial achieved the main research endpoint, with results that are both statistically significant and clinically meaningful. This clinical trial is a multicenter, randomized, double-blind, and placebo-controlled trial aimed at evaluating the effectiveness and safety of CU-20401 in patients with moderate to severe submental fat accumulation, with a total of 108 subjects enrolled. The analysis results show
Cutia Therapeutics Phase III Trial for Skin Treatments Presented in Annual CDA Meeting
Kerdis-B (02487.HK): The results of the phase III clinical trials of CU-40102 (external finasteride spray) and CU-30101 (topical lidocaine and prilocaine cream) were released at the 19th CDA Annual Meeting in China.
Gelonghui, November 28th, Kede-B (02487.HK) announced that the group's treatment of androgenetic alopecia product CU-40102 (topical finasteride spray) and CU-30101 for skin epidermal surgery (local topical lidocaine prilocaine cream) The Phase III clinical trial results in China were released in electronic poster form at the 19th China Physician Association Dermatologist Annual Meeting and National Cosmetic Dermatology Conference ("CDA Annual Meeting"). The group's research results have been selected for the CDA Annual Meeting for two consecutive sessions, representing the group's industry influence and cutting-edge level in the dermatology field. CU-40
Kedi-B (02487.HK) announced the results of the phase III clinical trials for two products in the mainland.
Ketodipe-B (02487.HK) announced that the results of the Phase III clinical trials of its androgenetic alopecia product CU-40102 and CU-30101 for use in epidermal surgery were presented at the National Dermatology and Aesthetics Society (CDA Annual Meeting) in china. Among them, the total hair count and terminal hair count of the subjects in the CU-40102 group in the target area of top hair loss were significantly better than the baseline in the placebo group, achieving both primary and major secondary endpoint indicators, and the efficacy began to show from the 12th week. As for CU-30101, its clinical trial results show
Cutia Therapeutics' Topical Acne Treatment Gets China Marketing Approval
Hong Kong stock movement | Code-B (02487) rises over 4% CU-10201 (4% minocycline foam agent for external use) has been approved for上市 by the National Medical Products Administration.
Cathay Pacific-B (02487) rose more than 4%, as of the deadline, up 4.14%, closing at 9.8 Hong Kong dollars, with a turnover of 4.0826 million Hong Kong dollars.
SciTech Holdings-B (02487.HK): CU-10201 (4% Minocycline Foam for External Use) has obtained approval from the National Medical Products Administration for marketing.
Great Wall News November 12th | Kodite-B (02487.HK) announced that the group's CU-10201 (4% topical minocycline foam) has been approved for marketing by the China National Medical Products Administration (NMPA). The indication of CU-10201 is for the treatment of non-nodular moderate to severe acne, and is suitable for use by children aged nine and above and adult patients. CU-10201 is the world's first and only topical minocycline approved for the treatment of common acne, and also the first topical minocycline approved for marketing by the NMPA with priority review and approval qualification in China. Rice
Cutia Therapeutics CEO Increase Shareholding in Company
KeDing-B (02487.HK) Chief Executive Officer and Executive Director Zhang Lele further increased shareholding.
Granolahui November 11th | Edico-B (02487.HK) announced that the board of directors received a notice from the company's CEO and executive director, Ms. Zhang Lele, that on November 8, 2024, she purchased a total of 5000 shares of the company's stock on the open market with her personal funds, at a total price of approximately 0.0493 million Hong Kong dollars. In October 2024, Ms. Zhang purchased a total of 0.028 million shares of stock on the open market, at a total price of approximately 0.3439 million Hong Kong dollars. After this shareholding increase, Ms. Zhang has accumulated a total purchase of 0.033 million shares of stock, at a total price of approximately 0.3932 million Hong Kong dollars, equivalent to the average price per share.
Cutia Therapeutics' Phase 2 Trial of Drug for Adipose Accumulation-Related Diseases Complete Database Lock
Cutia Therapeutics Records 130% Higher Revenue From Commercialized Products in Nine Months to September
HK stocks unusual movement, Kedi rose nearly 10%, the first three quarters of product revenue increased by about 1.3 times.
Gelonghui October 31st | KeDi-B (2487.HK) rose in the afternoon, rising nearly 10% at one point to HK$14.1. On the news front, the group announced that as of the end of September, the revenue from commercialized products was approximately 0.149 billion yuan, an increase of about 1.3 times year-on-year. (Gelonghui)
Kedi-B's revenue from commercialized products in the first three quarters is about 0.1489 billion yuan, a year-on-year increase of about 129.9%.
Kede-B (02487) announced that as of the nine months ended September 30, 2024, the group's commercialized product revenue was approximately RMB 0.1489 billion, achieving a positive growth of about 129.9% compared to the same period in 2023.
Kede Bi-B (02487.HK): The revenue from commercialized products in the first three quarters increased by 129.9% year-on-year.
KeDi-B (02487.HK) announced on October 31 that as of the nine months ending September 30, 2024, the group's commercialized product revenue was approximately RMB 0.1489 billion, recording a positive growth of about 129.9% compared to the same period in 2023.
Repurchase gatherings on October 30: Aia, Swire Pacific A, and others have repurchased one after another, with Aia spending 62.6635 million Hong Kong dollars.
According to hkex's disclosure on October 31, Aia, Swire Pacific A, and other companies repurchased shares.① Aia repurchased 1.0168 million shares of common stock on October 30, involving 62.6635 million Hong Kong dollars, with a repurchase price per share ranging from 62.6 Hong Kong dollars to 61.15 Hong Kong dollars. Since the repurchase authorization resolution, the cumulative number of repurchased securities is 0.319 billion shares, accounting for 2.837% of the number of issued shares when the ordinary resolution was passed.② Swire Pacific A
Cordis-B (02487): The clinical trial of CU-20401 (recombinant mutated collagenase) for the treatment of submental fat accumulation phase II has completed database lock.
Ketide-B (02487) announced the potential first-class new drug CU-20401 (recombinant mutated collagenase)...
October 21st Buyback Compilation | hsbc holdings, aia and others have successively repurchased, with hsbc holdings spending 0.102 billion Hong Kong dollars.
According to the disclosure documents released by hkex on October 22, hsbc holdings (00005.HK) and aia (01299.HK) repurchased shares. ① Hsbc holdings (00005.HK) repurchased 1.484 million shares of common stock on October 18, involving 0.102 billion Hong Kong dollars, with the repurchase price per share ranging from 69.1 Hong Kong dollars to 68.4 Hong Kong dollars. ② Aia (01299.HK) repurchased 1.002 million shares of common stock on October 21, involving 62.3921 million Hong Kong dollars, with the repurchase price per share ranging from 62.9 Hong Kong dollars.
Analysis
Price Target
No Data
No Data